Summary:
Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m2 was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity profile was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horowitz MH, Gale RP, Sondel PM et al. Graft-versus-leukemia reaction after bone marrow transplantation. Blood 1990; 75: 555–562.
Socié G, Salooja N, Cohen A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.
Sullivan KM . Graft-vs.-host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing Ltd: Malden, 2004, pp 635–664.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.
Martin PJ, Carpenter PA, Sanders JE, Flowers ED . Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004; 79: 221–228.
Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577–600.
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.
Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.
Muller-Bérat CN, van Putten LM, van Bekkum DW . Cytostatic drugs in the treatment of secondary disease following homologous bone marrow transplantation: extrapolation from the mouse to the primate. Ann NY Acad Sci 1966; 129: 340–354.
Santos GW, Tutschka PJ, Brookmeyer R et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21–28.
O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.
Orchard K, Blackwell J, Chase A et al. Autologous peripheral blood cell transplantation as treatment of severe life-threatening GVHD. Blood 1996; 88 (Suppl. 1): 421 (Abstr. 1673).
Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709–710.
Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–257.
Nousari CH, Brodsky R, Anhalt GJ et al. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 148–150.
Petri M, Jones RJ, Brodsky RA . High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166–173.
Drachman DB, Jones RJ, Brodsky RA . Treatment of refractory myasthemia: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol 2003; 53: 29–34.
Snowden JA, Passweg J, Moore JJ et al. Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482–488.
Tisdale JF, Dunn DE, Geller N et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomized trial. Lancet 2000; 356: 1554–1559.
Mayer J, Obořilová A, Krejčí M et al. Pulse cyclophosphamide in the treatment of steroid-recfractory GVHD. Bone Marrow Transplant 2003; 31 (Suppl. 1): S185 (Abstr. 534).
Mayer J, Doubek M, Brychtová Y, Krejčí M . Unconventional treatment of steroid-refractory acute GVHD: pulse cyclophosphamide and/or intra-arterial steroid administration. Bone Marrow Transplant 2004; 33 (Suppl. 1): S126 (Abstr. 718).
Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Akpek G, Boitnott JK, Lee LA et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903–3907.
Sato T, Sakamaki S, Nagaoka Y et al. Intra-mesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs. host disease in an allogeneic bone marrow transplantation patient. Am J Hematol 1997; 56: 277–280.
Shapira MY, Bloom AI, Or R et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol 2002; 119: 760–764.
Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224–1226.
Hsu B, May R, Carrum G et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28: 945–950.
Massenkeil G, Rackwitz S, Genvresse I et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899–903.
McCaul KG, Nevill TJ, Barnett MJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367–374.
Khoury H, Kashyap A, Adkins DR et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059–1064.
Remberger M, Aschan J, Barkholt J et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147–153.
Arai S, Margolis J, Zahurak M et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.
Van Lint MT, Uderzo C, Milone G et al. A GITMO randomized trial in steroid refractory acute graft-versus-host disease: 6-methylprednisolone with or without anti-thymocyte globulin. Bone Marrow Transplant 2004; 33 (Suppl. 1): S45 (Abstr. 281).
Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.
Couriel D, Saliba R, Hicks KC et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.
Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody. visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712–2719.
Biersack H, Trenschel R, Peceny R et al. Treatment of steroid refractory acute GVHD with Campath-1H. Bone Marrow Transplant 2004; 33 (Suppl. 1): S188 (Abstr. P726).
Nash RA, Furlong T, Storb R et al. Mycophenolate mofetil as salvage treatment for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Safety analysis. Blood 1997; 90 (Suppl. 1): 328 (Abstr. 459).
Benito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–1929.
Bolanos-Meade J, Jacobsohn D, Margolis J et al. Pentostatin in steroid refractory acute graft versus host disease. Blood 2002; 100: 420a (Abstr. 1628).
MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387–394.
Messner HA, Curtis JE, Minden MD et al. Clonogenic hemopoietic precursors in bone marrow transplantation. Blood 1987; 70: 1425–1432.
Benboubker L, Cartron G, Roingeard F et al. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte–macrophage colony-stimulating factor compared to bone marrow. Exp Hematol 2003; 31: 89–97.
Ravagnani F, Siena S, Bragni M et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Br J Cancer 1990; 26: 562–564.
Jones RJ, Barber JP, Vala MS et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85: 2742–2746.
Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.
Acknowledgements
This work was supported by a Research Grant of the Ministry of Health of the Czech Republic No. MZ 00065269705.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayer, J., Krejčí, M., Doubek, M. et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 35, 699–705 (2005). https://doi.org/10.1038/sj.bmt.1704829
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704829
Keywords
This article is cited by
-
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Bone Marrow Transplantation (2021)
-
Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis
Annals of Hematology (2020)
-
Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity
Annals of Hematology (2016)
-
Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease
Annals of Hematology (2005)